FINNENCE ▪ THE WIRE FILE
THE WIRE · № 56156
SEC Filing■ Unclear/unknown
ANET filed 4 on 2026-09-29
KINDSEC Filing
DIRECTION■ Unclear/unknown
SOURCES1
ENTITIES1
STORY SIZESTANDALONE
FIRST SEEN2026-09-29 00:00 UTC
LAST UPDATE2026-09-29 00:00 UTC
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
A Form 4 discloses an insider transaction but the filing text gives no share count, price, or buy/sell direction, so no signal can be inferred.
Routine insider filing with no disclosed transaction direction
CATALYST TO WATCH
Full Form 4 details showing buy or sell size
MAIN RISK
Misreading an unknown transaction as bullish or bearish
FULL DISPATCH
ANET (CIK 0001605809) filed a 4 on 2026-09-29.
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
SUBJECTArista Networks · ANET
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→INFERENCEfilings generate company commentary
New Phase 3 trial: A Study to Compare GNR-139 and Eylea® in Patients With nAMD — AO GENERIUM2026-09-28 12:00 UTC
New Phase 3 trial: A Study to Compare GNR-139 and Eylea® in Patients With nAMD — AO GENERIUM2026-09-28 12:00 UTC
→INFERENCEfilings generate company commentary
New Phase 3 trial: A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Established Cardiovascular Disease — Hoffmann-La Roche2026-09-28 12:00 UTC
New Phase 3 trial: A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Established Cardiovascular Disease — Hoffmann-La Roche2026-09-28 12:00 UTC
→INFERENCEfilings generate company commentary
New Phase 3 trial: A Trial to See if Daridorexant Can Help Adults and Elderly People With Insomnia Sleep Better During the Night and Function Better During the Day — Idorsia Pharmaceuticals Ltd.2026-09-28 12:00 UTC
New Phase 3 trial: A Trial to See if Daridorexant Can Help Adults and Elderly People With Insomnia Sleep Better During the Night and Function Better During the Day — Idorsia Pharmaceuticals Ltd.2026-09-28 12:00 UTC
→INFERENCEfilings generate company commentary
New Phase 3 trial: The Safety and Efficacy of HR19034 in Children With Myopia — Chengdu Suncadia Medicine Co., Ltd.2026-09-28 12:00 UTC
New Phase 3 trial: The Safety and Efficacy of HR19034 in Children With Myopia — Chengdu Suncadia Medicine Co., Ltd.2026-09-28 12:00 UTC
→INFERENCEfilings generate company commentary
New Phase 3 trial: An Open-Label, Safety and Efficacy Study of Cebranopadol in Participants With Acute Pain With Surgical or Non-Surgical Origin — Adneuris Therapeutics, Inc.2026-09-28 12:00 UTC
New Phase 3 trial: An Open-Label, Safety and Efficacy Study of Cebranopadol in Participants With Acute Pain With Surgical or Non-Surgical Origin — Adneuris Therapeutics, Inc.2026-09-28 12:00 UTC
→INFERENCEfilings generate company commentary
Phase 3 results posted: A Study of Vaccination With 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years — Janssen Research & Development, LLC2026-09-28 12:00 UTC
Phase 3 results posted: A Study of Vaccination With 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years — Janssen Research & Development, LLC2026-09-28 12:00 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.